BiotechTube

fingolimod (FTY720)

Phase 1/2Completed
0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Rett's Syndrome

Conditions

Rett's Syndrome

Trial Timeline

Aug 1, 2013 → Apr 1, 2018

NCT ID
NCT02061137

About fingolimod (FTY720)

fingolimod (FTY720) is a phase 1/2 stage product being developed by Novartis for Rett's Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT02061137. Target conditions include Rett's Syndrome.

What happened to similar drugs?

3 of 3 similar drugs in Rett's Syndrome were approved

Approved (3) Terminated (0) Active (0)
✅Esomeprazole + Aspirin + RofecoxibAstraZenecaApproved
✅Esomeprazole + LansoprazoleAstraZenecaApproved
✅Esomeprazole MagnesiumAstraZenecaApproved

Hype Score Breakdown

Clinical
9
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT02061137Phase 1/2Completed
NCT01498887ApprovedCompleted
NCT00731523Phase 1Completed

Competing Products

4 competing products in Rett's Syndrome

See all competitors
ProductCompanyStageHype Score
Esomeprazole + Aspirin + RofecoxibAstraZenecaApproved
43
Esomeprazole + LansoprazoleAstraZenecaApproved
43
Esomeprazole MagnesiumAstraZenecaApproved
43
ChemotherapyPacific BiosciencesPre-clinical
23